Bronchiolitis Obliterans Syndrome Bos Market Size

DelveInsight's 'Bronchiolitis Obliterans Syndrome (BOS)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Bronchiolitis Obliterans Syndrome (BOS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Bronchiolitis Obliterans Syndrome (BOS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Bronchiolitis Obliterans Syndrome (BOS) - Disease Understanding and Treatment Algorithm

According to National Institute of Health, Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Bronchiolitis Obliterans Syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous. Regardless of the clinical history, the primary pathologic correlate of BOS is bronchiolitis obliterans, a condition of intraluminal airway fibrosis.

Bronchiolitis Obliterans Syndrome (BOS) remains the major problem which cease long-term survival after lung transplantation. Treatment and prevention of BOS is quite challenging. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. An important focus of treatment of BOS patients is optimizing immunosuppression to prevent further lung allograft rejection. Current treatment consists primarily of augmenting immunosuppression by changing medications within therapeutic classes, by adding medications, or by applying non-medicinal immuno-modulating therapies. Currently for the treatment of BOS immunosuppressive agents, macrolide antibiotics, rescue therapies, surgical therapies and other treatment options are followed.

The DelveInsight Bronchiolitis Obliterans Syndrome market report gives the thorough understanding of the Bronchiolitis Obliterans Syndrome by including details such as disease introduction, causes, pathophysiology, signs and symptoms, developmental and clinical aspects of Bronchiolitis Obliterans Syndrome, genetics of BOS, pathophysiology, clinical manifestations in BOS and diagnosis. It also provides treatment algorithms and treatment guidelines for Bronchiolitis Obliterans Syndrome in the US, Europe, and Japan.


Bronchiolitis Obliterans Syndrome (BOS) Epidemiology

According to European Medicines Agency stated that Bronchiolitis Obliterans Syndrome affects less than approximately 1 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 52,000 people which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Bronchiolitis Obliterans Syndrome in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

• Total Prevalent Cases of Bronchiolitis Obliterans Syndrome

• Total Diagnosed Prevalent Population of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant recipients

• Total Diagnosed Prevalent Population of Bronchiolitis Obliterans Syndrome (BOS) in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients

• Gender- specific Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS)

• Grade Specific Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS)

A European study titled as “The impact of cytolytic therapy on bronchiolitis obliterans syndrome” conducted by H. Date et al stated that between July 1988 and July 1994, 233 patients underwent lung transplantation at Barnes-Jewish Hospital. Among 207 recipients (88.8%) who survived more than 3 months, 81 recipients (39%) had development of BOS; 48 of these patients underwent 64 courses of treatment with a cytolytic agent (antilymphocyte globulin, antithymocyte globulin, or OKT3 monoclonal antibody). The cases of BOS were retrospectively analyzed to determine the impact of cytolytic therapy. The outcomes of the study was that the 4-year survival rate was significantly greater in recipients without BOS than in those with BOS.

As per a recent study conducted by K. Rachana et al, titled as “Bronchiolitis Obliterans (Obliterative Bronchiolitis, Constrictive Bronchiolitis)” stated that lung transplantation or hematopoietic stem cell transplantation (HSCT) leads to Bronchiolitis Obliterans Syndrome (BOS). Mostly the long term survivors are prone to BOS along with about 5% to 14% of HSCT recipients also develop bronchiolitis obliterans syndrome which is pulmonary graft vs. host disease and can present several months to years after transplantation. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation.


Bronchiolitis Obliterans Syndrome (BOS) Drug Chapters

This segment of the Bronchiolitis Obliterans Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Bronchiolitis Obliterans Syndrome, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Bronchiolitis Obliterans Syndrome and awareness of the disease. The overall dynamics of Bronchiolitis Obliterans Syndrome market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Breath Therapeutics, Incyte Corporation, Genentech will significantly increase the market during the forecast period (2019-2028).   


Bronchiolitis Obliterans Syndrome (BOS) Market Outlook

The Bronchiolitis Obliterans Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Unfortunately, there is no approved therapy for Bronchiolitis Obliterans Syndrome in the market. Treatment and prevention of BOS is a challenging task. A successful treatment of BOS can be defined as stabilization of the current situation of the patient. Current management alternatives primarily includes augmenting immunosuppression by changing medications within therapeutic classes, by adding medications, or by applying non-medicinal immune-modulating therapies. In addition, antibiotics and other substitutes such as Leukotriene Receptor Antagonist, Anti-Fibrotic Agents, Cell-cycle Inhibitors, etc. The antibiotics and the other alternatives can also be used as a combination treatment at appropriate instances. Employment of Immunosuppressant Regimen can improve the outcomes for BOS. Current immune suppressive regimens majorly includes calcineurin inhibitor, corticosteroids and few others such as mTOR inhibitors/proliferation signal inhibitors and anti-lymphocyte antibody preparations. Treatment for Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation (HSCT) is based on reinstitution or augmentation of immunosuppressive therapy with high-dose systemic corticosteroids and other agents, namely cyclosporine A (CsA) and tacrolimus.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Bronchiolitis Obliterans Syndrome in 7MM is expected to change from 2019-2028.


Bronchiolitis Obliterans Syndrome (BOS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Bronchiolitis Obliterans Syndrome (BOS) such as Liposomal Cyclosporine A (Breath Therapeutics), Ruxolitinib (Incyte Corporation), Pirfenidone (Genentech), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Bronchiolitis Obliterans Syndrome (BOS) market. 


Bronchiolitis Obliterans Syndrome (BOS) Report Insights

• Patient Population

• Therapeutic Approaches

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Bronchiolitis Obliterans Syndrome (BOS) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Bronchiolitis Obliterans Syndrome (BOS) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Bronchiolitis Obliterans Syndrome (BOS)market

• Organize sales and marketing efforts by identifying the best opportunities for Bronchiolitis Obliterans Syndrome (BOS)market

• To understand the future market competition in the Bronchiolitis Obliterans Syndrome (BOS) market.

1. Key Insights

2. Bronchiolitis Obliterans Syndrome (BOS) Market Overview at a Glance

2.1. Market Share (%) Distribution of Bronchiolitis Obliterans Syndrome (BOS) in 2017

2.2. Market Share (%) Distribution of Bronchiolitis Obliterans Syndrome (BOS) in 2028

3. Disease Background and Overview: Bronchiolitis Obliterans Syndrome (BOS)

3.1. Introduction

3.2. Signs and Symptoms

3.3. Causes

3.4. Risk factors

3.5. Pathogenesis

3.6. Biomarkers

3.7. Diagnosis

3.8. Differential Diagnosis

3.9. Diagnostic Algorithm

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Patient Population of Bronchiolitis Obliterans Syndrome (BOS)

5. Country Wise-Epidemiology of Bronchiolitis Obliterans Syndrome (BOS)

5.1. Registries and Studies for aHSCT and LTx

5.2. What do experts say?

5.3. United States

5.3.1. Assumptions and Rationale

5.3.2. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United States

5.3.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United States

5.3.4. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United States

5.3.5. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United States

5.3.6. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United States

5.4. EU5 Countries

5.4.1. Assumptions and Rationale

5.5. Germany

5.5.1. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Germany

5.5.2. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Germany

5.5.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Germany

5.5.4. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Germany

5.5.5. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Germany

5.6. France

5.6.1. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in France

5.6.2. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in France

5.6.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in France

5.6.4. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in France

5.6.5. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in France

5.7. Italy

5.7.1. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Italy

5.7.2. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Italy

5.7.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Italy

5.7.4. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Italy

5.7.5. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Italy

5.8. Spain

5.8.1. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Spain

5.8.2. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Spain

5.8.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Spain

5.8.4. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Spain

5.8.5. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Spain

5.9. United Kingdom

5.9.1. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United Kingdom

5.9.2. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United Kingdom

5.9.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United Kingdom

5.9.4. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United Kingdom

5.9.5. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United Kingdom

5.10. Japan

5.10.1. Assumptions and Rationale

5.10.2. Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Japan

5.10.3. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Japan

5.10.4. Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Japan

5.10.5. Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Japan

5.10.6. Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Japan

6. Treatment

6.1. Immunosuppressant Regimen

6.1.1. Calcineurin Inhibitors

6.1.2. Corticosteroids

6.1.3. mTOR inhibitors/proliferation signal inhibitors: Sirolimus

6.1.4. Induction immunosuppression

6.2. Macrolide Antibiotics

6.3. Rescue Therapy (Extracorporeal photopheresis)

6.4. Surgical Therapies

6.5. Other treatment options

6.5.1. Cell-cycle inhibitors

6.5.2. Co-stimulation blocker: Belatacept

6.5.3. Leukotriene Receptor Antagonist

6.5.4. HMG-CoA Inhibition

6.5.5. Combination therapy

7. Treatment Guidelines

8. Treatment Algorithm

9. Unmet Needs

10. Emerging Drugs

10.1. Key Cross Competition

10.2. Liposomal Cyclosporine A: Breath Therapeutics

10.2.1. Product Description

10.2.2. Other Development Activities

10.2.3. Clinical Development

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3. Ruxolitinib: Incyte Corporation

10.3.1. Product Description

10.3.2. Other Development Activities

10.3.3. Clinical Development

10.3.4. Product Profile

10.4. Pirfenidone: Genentech

10.4.1. Product Description

10.4.2. Other Development Activities

10.4.3. Clinical Development

10.4.4. Product Profile

11. Bronchiolitis Obliterans Syndrome (BOS): 7 Major Market Analysis

11.1. Key Findings

11.2. Market Size of Bronchiolitis Obliterans Syndrome (BOS) in 7MM

12. The United States Market Outlook

12.1. United States Market Size

12.1.1. Total Market size of Bronchiolitis Obliterans Syndrome (BOS)

12.1.2. Market Size by Therapies

13. EU-5 Countries: Market Outlook

13.1. Germany

13.1.1. Total Market size of Bronchiolitis Obliterans Syndrome (BOS) in Germany

13.1.2. Market Size by Emerging Therapies

13.2. France

13.2.1.1. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS)

13.2.1.2. Market Size by Emerging Therapies

13.3. Italy

13.3.1. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS)

13.3.2. Market Size by Emerging Therapies

13.4. Spain

13.4.1. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS)

13.4.2. Market Size by Emerging Therapies

13.5. United Kingdom

13.5.1. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS)

13.5.2. Market Size by Emerging Therapies

14. Japan: Market Outlook

14.1. Japan market Size

14.1.1. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS)

14.1.2. Market Size by Emerging Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Table 1: Total Diagnosed Population of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM (2017-2028)

Table 2: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United States (2017-2028)

Table 3: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United States (2017-2028)

Table 4: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United States (2017-2028)

Table 5: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United States (2017-2028)

Table 6: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United States (2017-2028)

Table 7: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Germany (2017-2028)

Table 8: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Germany (2017-2028)

Table 9: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Germany (2017-2028)

Table 10: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Germany (2017-2028)

Table 11: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Germany (2017-2028)

Table 12: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in France (2017-2028)

Table 13: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in France (2017-2028)

Table 14: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in France (2017-2028)

Table 15: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in France (2017-2028)

Table 16: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in France (2017-2028)

Table 17: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Italy (2017-2028)

Table 18: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Italy (2017-2028)

Table 19: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Italy (2017-2028)

Table 20: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Italy (2017-2028)

Table 21: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Italy (2017-2028)

Table 18: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Italy (2017-2028)

Table 23: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Spain (2017-2028)

Table 24: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Spain (2017-2028)

Table 25: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Spain (2017-2028)

Table 26: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Spain (2017-2028)

Table 27: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Spain (2017-2028)

Table 28: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United Kingdom (2017-2028)

Table 29: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United Kingdom (2017-2028)

Table 30: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United Kingdom (2017-2028)

Table 31: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Table 32: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Table 33: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Japan (2017-2028)

Table 34: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Japan (2017-2028)

Table 35: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Japan (2017-2028)

Table 36: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Japan (2017-2028)

Table 37: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Japan (2017-2028)

Table 38: Immunosuppressive Agents

Table 39: Comparison of emerging drugs under development

Table 40: Clinical Trial Description

Table 41: Clinical Trial Description

Table 42: Clinical Trial Description

Table 43: 7 Major Market Size of Bronchiolitis Obliterans Syndrome (BOS) in USD Million (2017-2028)

Table 44: United States Market Size of Bronchiolitis Obliterans Syndrome, USD Million (2017-2028)

Table 45: Market size of Bronchiolitis Obliterans Syndrome by therapies in United States, in USD Million (2017-2028)

Table 46: Market Size of Bronchiolitis Obliterans Syndrome in Germany, in USD Million (2017-2028)

Table 47: Market size of Bronchiolitis Obliterans Syndrome by therapies in Germany, in USD Million (2017-2028)

Table 48: Market Size of Bronchiolitis Obliterans Syndrome in France, in USD Million (2017-2028)

Table 49: Market size of Bronchiolitis Obliterans Syndrome by therapies in France, in USD Million (2017-2028)

Table 50: Market Size of Bronchiolitis Obliterans Syndrome in Italy, in USD Million (2017-2028)

Table 51: Market size of Bronchiolitis Obliterans Syndrome by therapies in Italy, in USD Million (2017-2028)

Table 52: Market Size of Bronchiolitis Obliterans Syndrome in Spain, in USD Million (2017-2028)

Table 53: Market size of Bronchiolitis Obliterans Syndrome by therapies in Spain, in USD Million (2017-2028)

Table 54: Market Size of Bronchiolitis Obliterans Syndrome in the UK, in USD Million (2017-2028)

Table 55: Market size of Bronchiolitis Obliterans Syndrome by therapies in the UK, in USD Million (2017-2028)

Table 56: Market Size of Bronchiolitis Obliterans Syndrome in Japan, in USD Million (2017-2028)

Table 57: Market size of Bronchiolitis Obliterans Syndrome by therapies in Japan, in USD Million (2017-2028)

Figure 1: Overall pathogenesis of BOS

Figure 2: Algorithm for clinical evaluation of suspected bronchiolitis obliterans syndrome (BOS)

Figure 3: Total Diagnosed Population of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM (2017-2028)

Figure 4: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United States (2017-2028)

Figure 5: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United States (2017-2028)

Figure 6: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United States (2017-2028)

Figure 7: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United States (2017-2028)

Figure 8: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United States (2017-2028)

Figure 9: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Germany (2017-2028)

Figure 10: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Germany (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Germany (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Germany (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Germany (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in France (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in France (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in France (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in France (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in France (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Italy (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Italy (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Italy (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Italy (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Italy (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Italy (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Spain (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Spain (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Spain (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Spain (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in the United Kingdom (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in the United Kingdom (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in the United Kingdom (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Total Prevalent Population in Japan (2017-2028)

Figure 11: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Lung Transplant recipients in Japan (2017-2028)

Figure 12: Bronchiolitis Obliterans Syndrome (BOS) Total Diagnosed Prevalent Population in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients in Japan (2017-2028)

Figure 13: Bronchiolitis Obliterans Syndrome (BOS) Gender- specific Diagnosed Prevalence in Japan (2017-2028)

Figure 14: Bronchiolitis Obliterans Syndrome (BOS) Grade Specific Diagnosed Prevalence in Japan (2017-2028)

Figure 39: Unmet Needs of Bronchiolitis Obliterans Syndrome (BOS)

Figure 40: 7 Major Market Size of Bronchiolitis Obliterans Syndrome (BOS) in USD Million (2017-2028)

Figure 41: Market Size of Bronchiolitis Obliterans Syndrome in the United States, USD Millions (2017-2028)

Figure 42: Market size of Bronchiolitis Obliterans Syndrome by therapies in the US, in USD Million (2017-2028)

Figure 43: Market Size of Bronchiolitis Obliterans Syndrome in Germany, USD Million (2017-2028)

Figure 44: Market Size of Bronchiolitis Obliterans Syndrome by therapies, in Germany, in USD Million (2017-2028)

Figure 45: Market Size of Bronchiolitis Obliterans Syndrome in France, USD Million (2017-2028)

Figure 46: Market Size of Bronchiolitis Obliterans Syndrome by therapies, in France, in USD Million (2017-2028)

Figure 47: Market Size of Bronchiolitis Obliterans Syndrome in Italy, USD Million (2017-2028)

Figure 48: Market Size of Bronchiolitis Obliterans Syndrome by therapies in Italy, in USD Million (2017-2028)

Figure 49: Market Size of Bronchiolitis Obliterans Syndrome in Spain, USD Million (2017-2028)

Figure 50: Market Size of Bronchiolitis Obliterans Syndrome by therapies in Spain, in USD Million (2017-2028)

Figure 51: Market Size of Bronchiolitis Obliterans Syndrome in the UK, USD Million (2017-2028)

Figure 52: Market Size of Bronchiolitis Obliterans Syndrome by therapies in the UK, in USD Million (2017-2028)

Figure 53: Market Size of Bronchiolitis Obliterans Syndrome in Japan, USD Million (2017-2028)

Figure 54: Market Size of Bronchiolitis Obliterans Syndrome by therapies in Japan, in USD Million (2017-2028)

Figure 55: Market Drivers

Figure 56: Market Barriers

  • Tags:
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome (...
  • Bronchiolitis Obliterans Syndrome...

Forward to Friend

Need A Quote